Aytu BioPharma, Inc. AYTU PHARMA

Q: What is the current share price of Aytu BioPharma, Inc. (AYTU)?

As of 2026-09-19 21:16 PDT, Aytu BioPharma, Inc. (AYTU) trades at $2.19 on NasdaqCM. Its 52-week range is $1.71 to $2.90.

Q: What is the market capitalisation of AYTU?

Aytu BioPharma, Inc. (AYTU) has a market capitalisation of $23.51M on NasdaqCM.

Q: What is the P/E ratio of AYTU?

AYTU trades at a trailing price-to-earnings (P/E) ratio of -0.48. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.65.

Q: What is the return on equity (ROE) of AYTU?

AYTU has a return on equity (ROE) of -97.42%. Its return on capital employed (ROCE) is -12.81%.

Q: Is AYTU a good stock to buy?

This page provides a data-driven analysis of Aytu BioPharma, Inc. (AYTU), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Drug Manufacturers - Specialty & Generic · United States

https://aytubio.com

Company Profile ↓

$2.19

-4.37% 1Y

Mkt Cap$23.51M

P/E-0.48

P/B0.65

52W High$2.90

52W Low$1.71

Book Value$3.27

EPS (TTM)$-4.61

Company Overview

Aytu BioPharma, Inc., a pharmaceutical company, focuses on commercializing novel therapeutics in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT extended-release orally disintegrating tablets for patients from six years of age and above; Cotempla XR-ODT extended-release orally disintegrating tablets for patients from six to seventeen years old; and Metadate CD, a central nervous system stimulant indicated for the treatment of ADHD. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021. Aytu BioPharma, Inc. is headquartered in Denver, Colorado.

Why Investors Should Care

Steady Revenue Expansion

Revenue has grown at a 89.4% CAGR over the past five years.

Recent Developments

Jun 2025 Revenue of $66.38M (+1.8% YoY); net profit $-13.56M.
Trailing 12 Months Year-on-year growth — revenue -32.7%.
5-Year Trend Long-term compounding — revenue CAGR 89.4%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	89.42%
1 Year:	-32.70%

Stock Price Performance

1 Year:	-4.37%
6 Months:	-16.09%
3 Months:	-4.37%
1 Month:	-7.20%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish

52-Week Range 40% of range

$1.71 $2.90

Trend Signals

Price vs 50-DMABelow
Price vs 200-DMABelow
RSI (14)42.29 · Neutral

Price Performance

1M-7.20%

3M-4.37%

6M-16.09%

1Y-4.37%

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Compounding revenue at 89.4% over 5 years.

CONS

In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

-0.48

Industry PE

24.83

Forward P/E

-29.20

PEG Ratio

Book Value

$3.27

Price to Book

0.65

P/S

0.40

EV/EBITDA

-7.52

Dividend Yield

0.00%

Growth (CAGR)

Revenue 5Y

89.42%

Profit 5Y

Revenue (YoY)

-32.70%

Earnings (YoY)

Profitability & Returns

ROCE

-12.81%

ROE

-97.42%

ROA

-3.65%

Profit Margin

-60.17%

Op Margin

-32.74%

Gross Margin

64.78%

EPS (Latest Qtr)

$-0.53

EPS (TTM)

$-4.61

Balance Sheet & Liquidity

Debt/Equity

0.65

Quick Ratio

0.85

Current Ratio

1.12

Debt

$22.94M

Total Assets

$111.69M

Current Assets

Working Capital

Ownership

Promoter Holding

8.27%

Chg in Prom Hold

-1.84%

FII / Inst Holding

35.96%

Chg in FII Hold

-0.63%

Financial Snapshot

Enterprise Value

$23.51M

Total Revenue (TTM)

$56.60M

EBITDA

$-2.62M

Free Cash Flow

$-1.19M

Operating Cash Flow

$1.68M

Shares Outstanding

10.73M

Gross Margin

64.78%

Payout Ratio

0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	AYTU Aytu BioPharma, Inc. PHARMA	2.19	-0.48	$23.51M	0.00%	-12.81%	-97.42%	89.42%	-
2	LLY Eli Lilly and Company SPXR3KPHARMA	1,123.91	37.80	$1.00T	0.60%	-	102.29%	7.20%	11.41%
3	JNJ Johnson & Johnson SPXR3KPHARMA	269.12	31.22	$648.55B	1.98%	14.88%	25.74%	2.43%	4.76%
4	ABBV AbbVie Inc. SPXR3KPHARMA	248.78	70.48	$439.62B	2.78%	10.47%	-129.24%	1.75%	-29.06%
5	MRK Merck & Co., Inc. SPXR3KPHARMA	148.46	118.77	$366.28B	2.31%	-	6.96%	5.64%	10.01%
6	UNH UnitedHealth Group Incorporated SPXR3KPHARMA	400.84	25.74	$359.79B	2.47%	9.74%	14.15%	10.40%	5.43%
7	NVS Novartis AG PHARMA	137.70	20.80	$261.73B	3.36%	21.09%	30.35%	9.25%	26.22%
8	AZN AstraZeneca PLC NDXPHARMA	160.04	23.99	$248.20B	2.00%	15.97%	21.96%	9.82%	45.96%
9	TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA	603.02	32.49	$222.97B	0.29%	8.14%	13.51%	8.81%	12.95%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Mar 2014	May 2014	Sep 2014	Nov 2014	Dec 2014	Feb 2015	Mar 2015	Sep 2015	Dec 2015	Mar 2016	Sep 2016	Dec 2016	Mar 2017	Sep 2017	Dec 2017	Mar 2018	Sep 2018	Dec 2018	Mar 2019	Sep 2019	Dec 2019	Mar 2020	Sep 2020	Dec 2020	Mar 2021	Sep 2021	Dec 2021	Mar 2022	Sep 2022	Dec 2022	Mar 2023	Sep 2023	Dec 2023	Mar 2024	Sep 2024	Dec 2024	Mar 2025	Sep 2025	Dec 2025	Mar 2026
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	13.52M	15.15M	13.48M	21.90M	23.12M	24.20M	27.66M	26.28M	22.73M	17.82M	18.75M	14.03M	16.57M	16.22M	18.45M	13.89M	15.16M	12.41M
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	9.46M	8.90M	-452.00K	12.46M	12.30M	12.69M	18.03M	17.29M	12.74M	13.04M	14.60M	10.36M	11.98M	10.79M	12.81M	9.19M	9.62M	7.60M
Operating Income	-	-11.13K	-2.09M	-15.29K	-1.58M	-9.40K	-1.81M	-2.16M	-3.01M	-3.23M	-5.97M	-4.20M	-4.86M	-4.36M	-3.99M	-7.52M	-3.42M	-4.55M	-4.30M	-4.74M	-4.97M	-4.79M	-3.56M	-5.58M	-25.67M	-27.70M	-11.29M	-53.42M	-1.81M	-6.87M	-8.56M	-867.00K	3.15M	-1.60M	-930.00K	-1.70M	2.42M	-1.50M	-1.97M	-4.06M
Net Income	-1.68M	-11.82K	-2.11M	-15.75K	-1.62M	-9.88K	-1.84M	-2.28M	-3.33M	-7.27M	-5.72M	-4.82M	-5.22M	-4.25M	-3.67M	-2.82M	-3.45M	-4.66M	-4.50M	-4.93M	-214.25K	-5.33M	-4.31M	-9.53M	-25.46M	-27.85M	-11.55M	-53.29M	-701.00K	-6.69M	-7.20M	-8.12M	-220.00K	-2.89M	1.47M	788.00K	3.99M	1.97M	-10.58M	-5.62M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-0.35	-0.72	-1.41	-1.09	-8.74	-35.90	-0.28	-2.15	-1.93	-1.48	-0.04	-0.52	-0.15	-0.26	0.21	-0.08	-1.05	-0.53
R&D Expense	1.24M	-	933.75K	-	789.97K	-	694.18K	855.87K	1.31M	1.14M	232.02K	263.46K	279.05K	140.95K	-277.49K	114.14K	155.88K	149.03K	108.90K	78.02K	66.67K	78.50K	183.00K	286.00K	390.00K	1.65M	4.47M	3.28M	1.06M	1.71M	856.00K	595.00K	521.00K	611.00K	426.00K	522.00K	162.00K	0	0	0

Profit & Loss (Annual)

Figures in USD.

Metric	Aug 2006	Aug 2007	Aug 2008	Aug 2009	Aug 2010	Aug 2011	Aug 2012	Aug 2013	Jun 2014	Jun 2015	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Revenue	-	-	-	-	-	-	-	-	58.93K	261.78K	2.56M	3.22M	3.66M	7.32M	27.63M	65.63M	96.67M	107.40M	65.18M	66.38M
Gross Profit	-	-	-	-	-	-	-	-	-	-	-	-	-	-	19.35M	29.20M	52.28M	66.63M	49.05M	45.83M
Operating Income	-	-	-	-	-	-133.62K	-56.36K	-52.41K	-6.35M	-7.63M	-21.70M	-20.13M	-19.70M	-16.85M	-21.13M	-58.87M	-109.91M	-17.07M	-1.59M	-7.83M
Net Income	-70.44K	-48.95K	-57.17K	-58.89K	-60.27K	-136.80K	-59.67K	-57.32K	-5.58M	-7.72M	-28.18M	-22.51M	-10.19M	-27.13M	-13.62M	-58.29M	-108.78M	-17.05M	-15.84M	-13.56M
Diluted EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-3.48	-74.01	-5.11	-	-
R&D Expense	-	-	-	-	-	-	-	-	3.93M	3.22M	6.13M	959.86K	167.59K	589.07K	1.72M	5.62M	12.66M	4.09M	2.77M	1.33M

Balance Sheet (Annual)

Figures in USD.

Metric	Feb 2005	Aug 2005	Aug 2006	Aug 2007	Aug 2008	Aug 2009	Aug 2010	Aug 2011	Aug 2012	Jun 2013	Aug 2013	Jun 2014	Jun 2015	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Total Assets	-	-	-	-	-	-	-	22.84K	12.65K	-	9.67K	12.02M	18.19M	24.34M	15.00M	21.06M	34.72M	153.29M	265.67M	137.62M	136.46M	118.09M	124.18M
Total Equity	100	20.42K	57.95K	18.81K	25.96K	-13.58K	-55.61K	-35.59K	-69.72K	9.81M	-110.86K	5.37M	15.62M	10.09M	4.00M	13.42M	7.09M	95.02M	137.57M	44.31M	39.36M	27.72M	18.97M
Cash & Equivalents	-	-	-	-	-	-	-	-	-	2.91M	-	2.64M	7.35M	8.05M	802.33K	7.01M	11.04M	48.08M	49.65M	19.36M	22.98M	20.01M	30.95M
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	15.00M	14.71M	10.88M	10.89M
Total Liabilities	-	-	-	-	-	-	-	-	-	-	-	6.65M	2.57M	14.26M	11.00M	7.64M	27.63M	58.28M	128.10M	93.31M	97.11M	-	-
Current Liabilities	-	-	-	-	-	-	-	58.43K	82.36K	-	120.53K	6.09M	1.48M	10.10M	3.61M	3.39M	5.37M	28.76M	109.44M	64.44M	69.02M	62.23M	63.06M

Cash Flows (Annual)

Figures in USD.

Metric	Aug 2011	Aug 2012	Aug 2013	Jun 2014	Jun 2015	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Operating Cash Flow	-64.82K	-37.85K	-37.70K	-	-	-	-13.83M	-15.94M	-13.83M	-28.37M	-25.96M	-28.82M	-5.13M	-1.39M	-1.94M
Investing Cash Flow	-	-	-	-	-	-	-3.53M	-484.29K	-1.06M	-5.66M	-2.78M	-3.25M	-117.00K	-329.00K	-2.56M
Financing Cash Flow	67.27K	33.97K	39.46K	-	-	-	10.19M	22.66M	19.08M	71.07M	30.31M	1.53M	8.87M	-1.26M	15.44M
Capital Expenditure	-	-	-	-9.30K	-0	-252.93K	-111.61K	-74.71K	-59.85K	-0	-	-	-	-329.00K	-228.00K
Free Cash Flow	-	-	-	-	-	-	-13.94M	-16.02M	-13.89M	-28.37M	-	-	-	-1.72M	-2.17M

Ratios (Annual)

Figures in %.

Metric	Aug 2006	Aug 2007	Aug 2008	Aug 2009	Aug 2010	Aug 2011	Aug 2012	Aug 2013	Jun 2014	Jun 2015	Jun 2016	Jun 2017	Jun 2018	Jun 2019	Jun 2020	Jun 2021	Jun 2022	Jun 2023	Jun 2024	Jun 2025
Gross Margin %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	70.0%	44.5%	54.1%	62.0%	75.3%	69.0%
Operating Margin %	-	-	-	-	-	-	-	-	-10,770.3%	-2,915.5%	-847.0%	-624.7%	-538.2%	-230.1%	-76.5%	-89.7%	-113.7%	-15.9%	-2.4%	-11.8%
Net Margin %	-	-	-	-	-	-	-	-	-9,466.8%	-2,950.3%	-1,099.7%	-698.7%	-278.3%	-370.6%	-49.3%	-88.8%	-112.5%	-15.9%	-24.3%	-20.4%
ROE %	-121.6%	-260.3%	-220.3%	433.6%	108.4%	384.3%	85.6%	51.7%	-103.9%	-49.5%	-279.4%	-562.7%	-75.9%	-382.8%	-14.3%	-42.4%	-245.5%	-43.3%	-57.2%	-71.5%
ROCE %	-	-	-	-	-	375.4%	80.8%	47.3%	-107.1%	-45.7%	-152.4%	-176.7%	-111.5%	-57.4%	-17.0%	-37.7%	-150.2%	-25.3%	-2.8%	-12.8%

Shareholding Pattern

Insiders

8.27%

Institutions

35.96%

Public Float

39.20%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Nantahala Capital Management, LLC	10.13%	1.09M	$2.30M
2	Stonepine Capital Management, LLC	8.51%	912.92K	$1.94M
3	AWM Investment Company, Inc.	5.77%	619.57K	$1.31M
4	Vanguard Capital Management LLC	2.43%	261.15K	$553.63K
5	Crown Advisors Management, Inc.	1.86%	200.00K	$424.00K
6	Diadema Partners LP	1.38%	148.55K	$314.92K
7	Renaissance Technologies, LLC	0.98%	104.82K	$222.22K
8	Two Sigma Investments, LP	0.98%	105.33K	$223.29K
9	Geode Capital Management, LLC	0.87%	93.65K	$198.53K
10	Citadel Advisors Llc	0.46%	49.41K	$104.76K

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for AYTU

Google News Mon, 24 Aug 2026

AYTU | AYTU BioPharma, Inc. Common Financials - Revenue Breakdown - Quiver Quantitative

<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTE5jNVRlX29BRmFhZnNac1M1cWZCMFh1dFdZMzdseUJwbDFGNGFUUkhVOUIxQVhsQXRmZE5JT1VXRGRPMndnYXpweHoxeVpOaURUVlQzcmtIXzNfLWsyU3RWYWg3QTF6Q1NMY1VNQm5kdlJyLUotdnJN?oc=5" target="_blank">AYTU | …

Google News hu, 16 Jul 2026

New Strong Sell Stocks for July 16th - finance.yahoo.com

<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxNMWpOZnVXYXBHbDFhU2w5ekRDVlI0N0ZoUFdSWnRuczV4QzktSVZYZVI2LUVqZTR2ZEQ4VnhuMldZRGxVWFg2OGpYZHZDOThFb1ZLd2VkaEJYcDB2SVY4ZEhoczU4aEtheDJqbnVpY0FmVjd2ZkVrcC1raGNCT1g0ZDZKSTU3SzlXbHZuRE…

Google News Fri, 26 Jun 2026

AYTU Forecast — Price Target — Prediction for 2027 - tradingview.com

<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE5uSmJxYV9WRkhJUVhjLTdfeENyR1FvaFBIRTEtT1NMbjEyRHBUdTNQUWpHd3hIX1JtMFpqNzFmbnFfZENqYzEzZW15R0hKckZGS2VyQ1dTblVscEJXMllpYmVDWU5OUHhxTUpXSHRncDhrdWdWcHpqYXdR?oc=5" target="_blank">AYT…

Google News Sat, 20 Dec 2025

Aytu BioPharma, Inc. (NASDAQ:AYTU) Stock Catapults 28% Though Its Price And Business Still Lag The Industry - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi4AFBVV95cUxPcnZzdTJGejRLVDdmOW1zblczTS1tVWloVjU2NE83UHJwWDJVS2xlZ2lBUmR5OWtnZG9WbzRadHhpekkwREo0aWdSbkR2cmtra29hOEh0ODRKUmRKOEZjMk5VNVZBMEVKdHpKX0pLbjFGc0JfRFJYMHhyUTZNdmk1WFRManozUElFTDM4Z3…

Google News Fri, 14 Aug 2026

Aytu BioPharma (AYTU) investor and foundation each report 4.99% beneficial stake - Stock Titan

<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxOWlJ1Zm1DeEEyVTVLUUYwRTJtanlZeEJUSUxrbnFyeWdVR2M3S05uMVFyNWNkdWJLUS1WQ2ZheDQ4OFZySnc4LVRLNDB2dVpWdFZuYTZVcHF5dktRcDUxV09LTjF0RVFoSTJMMmtMZUhGMkMwTUdSa09HUWFSUVdFZVRRVjJfaGtrWDZnRl…

Google News Fri, 04 Sep 2026

Aytu BioScience Inc (AYTU) Key Financial Ratios – Valuation, Profitability & More - Value Research

<a href="https://news.google.com/rss/articles/CBMijwFBVV95cUxQbkswbG14QVNTTG1ick5IbXZsUjBpYk4wV3V3ZmlxSVFkT01KRTNmZm1mN0htQUlEbGpLdmtJSzIzVUQtN3FxWjNHWjd1YXlpZnY5X1B1OHBQTV8wX3E1b09aRnRpeDZNSXpKRV9NT2FCNmlCNDlaaUgwNnBIeGFFZVBaamRZdGY0anI0WF…

AYTU — Frequently Asked Questions

What is the current share price of Aytu BioPharma, Inc. (AYTU)?

As of 2026-09-19 21:16 PDT, Aytu BioPharma, Inc. (AYTU) trades at $2.19 on NasdaqCM. Its 52-week range is $1.71 to $2.90.

What is the market capitalisation of AYTU?

Aytu BioPharma, Inc. (AYTU) has a market capitalisation of $23.51M on NasdaqCM.

What is the P/E ratio of AYTU?

AYTU trades at a trailing price-to-earnings (P/E) ratio of -0.48. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.65.

What is the return on equity (ROE) of AYTU?

AYTU has a return on equity (ROE) of -97.42%. Its return on capital employed (ROCE) is -12.81%.

Is AYTU a good stock to buy?

This page provides a data-driven analysis of Aytu BioPharma, Inc. (AYTU), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

Aytu BioPharma, Inc. AYTU PHARMA

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

AYTU | AYTU BioPharma, Inc. Common Financials - Revenue Breakdown - Quiver Quantitative

New Strong Sell Stocks for July 16th - finance.yahoo.com

AYTU Forecast — Price Target — Prediction for 2027 - tradingview.com

Aytu BioPharma, Inc. (NASDAQ:AYTU) Stock Catapults 28% Though Its Price And Business Still Lag The Industry - simplywall.st

Aytu BioPharma (AYTU) investor and foundation each report 4.99% beneficial stake - Stock Titan

Aytu BioScience Inc (AYTU) Key Financial Ratios – Valuation, Profitability & More - Value Research

AYTU — Frequently Asked Questions

What is the current share price of Aytu BioPharma, Inc. (AYTU)?

What is the market capitalisation of AYTU?

What is the P/E ratio of AYTU?

What is the return on equity (ROE) of AYTU?

Is AYTU a good stock to buy?

Explore More